Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Arisa Paul"'
Autor:
Kamran A. Ali, Reecha D. Shah, Anukriti Dhar, Nina M. Myers, Cameron Nguyen, Arisa Paul, Jordan E. Mancuso, A. Scott Patterson, James P. Brody, Diane Heiser
Publikováno v:
SLAS Discovery, Vol 29, Iss 2, Pp 100129- (2024)
Combination therapies have improved outcomes for patients with acute myeloid leukemia (AML). However, these patients still have poor overall survival. Although many combination therapies are identified with high-throughput screening (HTS), these appr
Externí odkaz:
https://doaj.org/article/d398d84ef42d4d479a80deb827230e65
Autor:
Ivana Djuretic, Yik Andy Yeung, Renee Greer, Arisa Paul, Jeffrey Houser, Audrey Hollingsworth, Wei Wei Prior, Manu Kumar, Ruth Lan
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/2703b245d0a1409e93b1a79ae8c08c7c
Autor:
Markus D Lacher, Arisa Paul, Erica K. Anderson, Jordan Roselli, Marina Konopleva, Wade C. Anderson, Christine Gu, Steven Schaffert, Ryosuke Kita, Courtney D. DiNardo, Michelle A Richardson, Kathryn Vanderlaag, Zhihong Zeng, Abhishek Maiti, Marianne Santaguida
Publikováno v:
Blood. 138:3464-3464
INTRODUCTION: The combination of venetoclax (VEN) and a hypomethylating agent (HMA) such as decitabine (DEC) is frequently used in acute myeloid leukemia (AML) for patients unfit for standard chemotherapy. However, there is a subset of patients who d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::07c6dcfb727ae813596527a0b4e3a2ff
https://doi.org/10.1182/blood-2021-148891
https://doi.org/10.1182/blood-2021-148891
Autor:
Joseph Wagner, Wade C. Anderson, Laura Henry, Debbie C. Strachan, Kamran A Ali, Susanna Wen, Marianne Santaguida, Ryosuke Kita, Erica K. Anderson, Allen Ling, Arisa Paul, Joseph R. Pressley, Colin W. Dailey, Kristen Dempsey, Santhosh Balasubramanian, Steven Schaffert, Kathryn Vanderlaag, Markus D. Lacher
Publikováno v:
Journal of Clinical Oncology. 39:e19013-e19013
e19013 Background: Understanding the heterogeneity of AML is necessary for developing targeted drugs and diagnostics. A key measure of heterogeneity is the variance in response to treatments. Previously, we developed an ex vivo flow cytometry drug se
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::359c2636b23974120a10d8ad8de72706
https://doi.org/10.1200/jco.2021.39.15_suppl.e19013
https://doi.org/10.1200/jco.2021.39.15_suppl.e19013
Autor:
Anna Lorenc, Joshua Fisher, Varsha M. Patel, Rebecca Tarrant, Nubia Castillo-Mosquera, Elisabeth A. Nuttall, Carl Z. Beyers, Michael A. Simpson, Sean Whittaker, Silvia Aguilar-Duran, Kiran Dedhia, Ceri A. Roberts, Nelema Begum, Farrah S. Bakr, Isabella Tosi, Tracey J. Mitchell, Ricarda M. Hoffmann, Aria A. Ghasemi, Silvia Ferreira, Venu Pullabhatla, Emmanouil G Solomonidis, Rosie M. Butler, Anthony Bayega, Emanuele de Rinaldis, Wesley J. Woollard, Arisa Paul, Charlotte E. Flanagan, Antoinette Yoxall
Publikováno v:
Blood. 127(26)
Sezary syndrome (SS) is a leukemic variant of cutaneous T-cell lymphoma (CTCL) and represents an ideal model for study of T-cell transformation. We describe whole-exome and single-nucleotide polymorphism array–based copy number analyses of CD4+ tum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e9531a1f301d8633f688c2a0d6f3bbe
https://pubmed.ncbi.nlm.nih.gov/27121473
https://pubmed.ncbi.nlm.nih.gov/27121473